| 9/21/2021 |
What can $2.1 billion do for infection control in the wake of COVID-19? |
Business Wire |
... homes and other long-term care facilities, 7,900 dialysis clinics, and 4,700 ambulatory surgery centers, and will extend to other outpatient settings.” Who: Mackenzie Weise , MPH, CIC, Infection Prevention Clinical Program Manager for Clinical Surveillance & Compliance, Wolters Kluwer, is a trained epidemiologist with over 12 years of experience in the areas of infectious diseases, data analytics, and health informatics. She believes that the multi-billion-dollar investment the White ... |
| 9/17/2021 |
DermTech's Pigmented Lesion Assay Could Detect Melanoma at Its Earliest Stages, TRUST Study Suggests |
plasticsurgerypractice.com |
... pigmented lesions and enhance the early detection of melanoma, enabling clinicians to triage suspicious lesions more effectively to determine which lesions are high risk and should be biopsied versus safely managing benign lesions via clinical surveillance , researchers suggest, in the study. Examined Lesions The TRUST study was conducted in the US by examining a cohort of 2,575 PLA-tested lesions for evidence of melanoma detected during a protracted follow-up ... |
| 9/14/2021 |
DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine |
Business Wire |
... pigmented lesions and enhance the early detection of melanoma, enabling clinicians to triage suspicious lesions more effectively to determine which lesions are high risk and should be biopsied versus safely managing benign lesions via clinical surveillance . The TRUST study was conducted in the U.S. by examining a cohort of 2,575 PLA-tested lesions for evidence of melanoma detected during a protracted follow-up period of up to 36 months and ... |
| 9/14/2021 |
DermTech Study, Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden, Published in SKIN: The Journal Of Cutaneous Medicine | Financial Buzz |
financialbuzz.com |
... pigmented lesions and enhance the early detection of melanoma, enabling clinicians to triage suspicious lesions more effectively to determine which lesions are high risk and should be biopsied versus safely managing benign lesions via clinical surveillance .The TRUST study was conducted in the U.S. by examining a cohort of 2,575 PLA-tested lesions for evidence of melanoma detected during a protracted follow-up period of up to 36 months and ... |
| 9/7/2021 |
CliniComp Secures VHA Information System Contract Renewal |
govconwire.com |
... VA hospitals manage data associated with critical, medical-surgical, emergency and procedural care services.Sandra Johnson, senior vice president of client services at CliniComp, noted that the company has helped the department implement a clinical surveillance platform to manage COVID-19 cases, critical care coordination and supplies.The company also provides support services to the Defense Health Agency during the phased rollout of the MHS Genesis electronic health records system ... |
| 9/3/2021 |
CliniComp and Veterans Health Administration Renew Clinical Information System Contract |
PR Newswire |
... to meet their needs with our reliable and innovative solutions," said Sandra Johnson , Senior Vice President, Client Services."We are especially proud to have been able to facilitate swift implementation of the COVID-19 clinical surveillance monitoring solution at the onset of the pandemic for VA hospitals, providing the ability to monitor at-risk and rising-risk patients and manage resources such as ventilators, and improving critical care coordination and ... |
| 9/3/2021 |
CliniComp and Veterans Health Administration Renew Clinical Information System Contract |
tncontentexchange.com |
... to meet their needs with our reliable and innovative solutions," said Sandra Johnson, Senior Vice President, Client Services. "We are especially proud to have been able to facilitate swift implementation of the COVID-19 clinical surveillance monitoring solution at the onset of the pandemic for VA hospitals, providing the ability to monitor at-risk and rising-risk patients and manage resources such as ventilators, and improving critical care coordination and ... |
| 9/2/2021 |
4 hospital, payer execs who left their roles for digital health companies |
Becker's Hospital Review |
Several hospital and payer executives have left their roles to join digital health companies focused on virtual care and digital transformation since July. Here are the four executives: - Hayley Burgess, PharmD, was [appointed] chief clinical officer of VigiLanz, an EHR clinical surveillance company, the company announced Aug. 9. Prior to joining VigiLanz, Dr. Burgess served as assistant vice president of pharmacy services for HCA Healthcare in Nashville, Tenn. - Saurabha Bhatnagar ... |
| 8/20/2021 |
HCA, Google Health & 6 other health IT exec moves (HIT, fp) |
Becker's Hospital Review |
... the tech giant's global healthcare efforts since 2019. - Edmund Siy has been [named] chief information officer of Flemington, N.J.-based Hunterdon Healthcare. - Hayley Burgess, PharmD, was [appointed] chief clinical officer of VigiLanz, an EHR clinical surveillance company. Prior to joining VigiLanz, Dr. Burgess served as assistant vice president of pharmacy services for HCA Healthcare in Nashville, Tenn. - Lisa Collins has been [selected] as the senior vice president of global services ... |
| 8/18/2021 |
HCA exec tapped as new clinical chief of EHR clinical surveillance company |
Becker's Hospital Review |
VigiLanz, an EHR clinical surveillance company, recently named Hayley Burgess, PharmD, as its new chief clinical officer. Dr. Burgess brings more than 20 years of pharmacy services and medication management system experience to the role, in which she will oversee strategy for VigiLanz's clinical teams, lead regulatory affairs activities and support clinical innovations, according to an Aug. 9 news release. Prior to joining VigiLanz, Dr. Burgess served as assistant vice ... |
| 8/16/2021 |
UnityPoint Health expands strategic supply chain partnership with Premier Inc. |
jhconline.com |
... multi-year agreement, Premier experts will support UnityPoint Health’s optimization of insights and solutions derived from Premier’s Clinical and Margin PINC AI offerings. PINC AI encompasses Premier’s benchmarking, analytics, reporting, and clinical surveillance and decision support technologies. PINC AI provides actionable intelligence that improves outcomes, supports strong financial performance and enables success in new, alternative payment models. The financial terms of the agreement were not disclosed. [Learn ... |
| 8/11/2021 |
HIMSS21 tech news: patient intake mobile app, mobile care coordination |
Healthcare IT News |
HIMSS21 tech news: patient intake mobile app, mobile care coordination Photo: Marko Geber/Getty Images Vecna Technologies, a vendor of health IT focused on patient intake, clinical surveillance and telepresence robotics, has launched the Vecna HealthPass Mobile App. HealthPass is an extension of the company's digital patient intake portfolio, which is deployed in more than 2,000 health systems. The app empowers patients with a convenient, contactless experience to safely preregister ... |
| 8/10/2021 |
Vecna Technologies Launches HealthPass Mobile App for Patient Self Check-In at HIMSS21 Conference |
PR Newswire |
BURLINGTON, Mass. Vecna Technologies , a leading provider of healthcare information technologies focused on patient intake, clinical surveillance and telepresence robotics, announced today the launch of the Vecna HealthPass Mobile App at the HIMSS Global Health Conference and Exhibition August 9-13, 2021 in Las Vegas, Nevada . Vecna will showcase HealthPass at Caesars Forum Booth 437-24 in the HIMSS Consumerism and Patient Engagement Pavilion .Vecna Technologies CEO, Deborah Theobald , commented, "We are ... |
| 8/10/2021 |
Vecna Technologies Launches HealthPass Mobile App for Patient Self Check-In at HIMSS21 Conference |
tncontentexchange.com |
BURLINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Vecna Technologies , a leading provider of healthcare information technologies focused on patient intake, clinical surveillance and telepresence robotics, announced today the launch of the Vecna HealthPass Mobile App at the HIMSS Global Health Conference and Exhibition August 9-13, 2021 in Las Vegas, Nevada. Vecna will showcase HealthPass at Caesars Forum Booth 437-24 in the HIMSS Consumerism and Patient Engagement Pavilion. Vecna Technologies CEO, Deborah ... |
| 8/9/2021 |
VigiLanz Announces L. Hayley Burgess, Pharm.D, MBA, BCPP, CPPS as New Chief Clinical Officer |
PR Newswire |
MINNEAPOLIS , Aug. 9, VigiLanz , a life-saving clinical surveillance company, today announced that Dr. L. Hayley Burgess has been named as the organization's new Chief Clinical Officer. In this role, Dr. Burgess will provide leadership oversight and strategic vision for the VigiLanz clinical teams, as well as lead regulatory affairs activities, and support clinical innovations and product development.VigiLanz Announces L. Hayley Burgess, Pharm.D, MBA, BCPP, CPPS as New Chief ... |
| 8/9/2021 |
VigiLanz Announces L. Hayley Burgess, Pharm.D, MBA, BCPP, CPPS as New Chief Clinical Officer |
tmcnet.com |
TMCnet News [August 09, 2021] VigiLanz Announces L. Hayley Burgess, Pharm.D, MBA, BCPP, CPPS as New Chief Clinical Officer MINNEAPOLIS, Aug. 9, 2021 /PRNewswire/ -- VigiLanz , a life-saving clinical surveillance company, today announced that Dr. L. Hayley Burgess has been named as the organization's new Chief Clinical Officer. In this role, Dr. Burgess will provide leadership oversight and strategic vision for the VigiLanz clinical teams, as well as lead regulatory ... |
| 7/26/2021 |
Identifying Sequence Variants of 18 Hereditary Ovarian Cancer-Associated Genes in Chinese Epithelial Ovarian Cancer Patients |
hindawi.com |
... Epithelial Ovarian Cancer Patients Abstract Objectives. The causes of ovarian cancer (OC) have been confirmed to be closely related to genetic factors. Identifying sequence variants of hereditary ovarian cancer (HOC) susceptibility genes can increase clinical surveillance , facilitate early detection, and provide personalized treatment for patients. This study is aimed at investigating the variation frequency of HOC susceptibility genes in the Chinese population and providing information for the etiology and genetics ... |
| 7/2/2021 |
Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis |
asnjournals.org |
... history of documented COVID-19 prior to study entry. Outcomes were assessed following a disease-free washout period, and were: any SARS-CoV-2 infection (ie, detected by protocolized PCR tests or during routine clinical surveillance ), and clinically manifest COIVD-19 (consisting of only the latter). Results: Of 2337 consented participants who met study inclusion criteria, 9.5% were anti-SARS-CoV-2 IgG positive at baseline; 3.6% had a history ... |
| 7/1/2021 |
Abstract 2114: Horvath clock as a predictor of cancer risk in LFS patients |
aacrjournals.org |
... their sporadic counterparts. The lifetime cancer risk in TP53 mutation carriers is estimated to be ~73% for males and approaching 100% in females. Although improved survival outcomes have been demonstrated for carriers undergoing intense clinical surveillance , there is continued interest in identifying new environmental, genetic, and epigenetic risk factors that could improve our ability to predict disease onset and outcome. A number of studies have demonstrated age-associated DNA methylation ... |
| 6/24/2021 |
ESTRADIOL tablet [REMEDYREPACK INC.] |
National Institutes of Health |
... Get Label RSS Feed - View NDC Code(s)NEW! Updated June 23, 2021 If you are a consumer or patient please visit this version. Rx only ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There ... |